

Marilyn J Telen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9004656/publications.pdf>

Version: 2024-02-01

181
papers

7,483
citations

61984

43
h-index

58581

82
g-index

227
all docs

227
docs citations

227
times ranked

9593
citing authors

#	ARTICLE	IF	CITATIONS
1	Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. <i>Nature</i> , 2021, 590, 290-299.	27.8	1,069
2	Evolution of adverse changes in stored RBCs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17063-17068.	7.1	572
3	CD44 " A molecule involved in leukocyte adherence and T-cell activation. <i>Trends in Immunology</i> , 1989, 10, 423-428.	7.5	536
4	microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. <i>Blood</i> , 2010, 116, 4338-4348.	1.4	313
5	Translocation of Sickle Cell Erythrocyte MicroRNAs into <i>Plasmodium falciparum</i> Inhibits Parasite Translation and Contributes to Malaria Resistance. <i>Cell Host and Microbe</i> , 2012, 12, 187-199.	11.0	272
6	Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes. <i>American Journal of Hematology</i> , 2008, 83, 19-25.	4.1	244
7	Factors associated with survival in a contemporary adult sickle cell disease cohort. <i>American Journal of Hematology</i> , 2014, 89, 530-535.	4.1	235
8	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 727-740.	5.6	197
9	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. <i>Blood</i> , 2015, 125, 2656-2664.	1.4	178
10	Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. <i>American Journal of Hematology</i> , 2010, 85, 36-40.	4.1	167
11	The Genomic Analysis of Erythrocyte microRNA Expression in Sickle Cell Diseases. <i>PLoS ONE</i> , 2008, 3, e2360.	2.5	157
12	Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. <i>Blood</i> , 2003, 101, 3281-3287.	1.4	152
13	<i>MYH9</i> and <i>APOL1</i> are both associated with sickle cell disease nephropathy. <i>British Journal of Haematology</i> , 2011, 155, 386-394.	2.5	139
14	Adherence to Hydroxyurea Therapy in Children with Sickle Cell Anemia. <i>Journal of Pediatrics</i> , 2010, 156, 415-419.	1.8	138
15	Quantitative microscopy and nanoscopy of sickle red blood cells performed by wide field digital interferometry. <i>Journal of Biomedical Optics</i> , 2011, 16, 1.	2.6	137
16	Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-1 α 23 interactions. <i>Blood</i> , 2004, 104, 3774-3781.	1.4	135
17	Therapeutic strategies for sickle cell disease: towards a multi-agent approach. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 139-158.	46.4	116
18	Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. <i>Blood</i> , 2016, 127, 810-819.	1.4	107

#	ARTICLE	IF	CITATIONS
19	Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. <i>Blood</i> , 2007, 110, 2708-2717.	1.4	101
20	A comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes. <i>BMC Genomics</i> , 2015, 16, 952.	2.8	90
21	Validation of a novel point of care testing device for sickle cell disease. <i>BMC Medicine</i> , 2015, 13, 225.	5.5	81
22	Critical Factors in Basal Cell Adhesion Molecule/Lutheran-mediated Adhesion to Laminin. <i>Journal of Biological Chemistry</i> , 1999, 274, 728-734.	3.4	80
23	Red blood cell surface adhesion molecules: Their possible roles in normal human physiology and disease. <i>Seminars in Hematology</i> , 2000, 37, 130-142.	3.4	80
24	Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. <i>Transfusion</i> , 2015, 55, 1378-1387.	1.6	75
25	Erythrocyte Adhesion Receptors: Blood Group Antigens and Related Molecules. <i>Transfusion Medicine Reviews</i> , 2005, 19, 32-44.	2.0	70
26	Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. <i>Blood</i> , 2008, 112, 3474-3483.	1.4	68
27	Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. <i>Human Pathology</i> , 1994, 25, 1043-1049.	2.0	66
28	Depression, quality of life, and medical resource utilization in sickle cell disease. <i>Blood Advances</i> , 2017, 1, 1983-1992.	5.2	66
29	Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia. <i>PLoS ONE</i> , 2014, 9, e101301.	2.5	64
30	Impaired adenosine-5â€™-triphosphate release from red blood cells promotes their adhesion to endothelial cells: A mechanism of hypoxemia after transfusion*. <i>Critical Care Medicine</i> , 2011, 39, 2478-2486.	0.9	63
31	Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. <i>Transfusion</i> , 2008, 48, 917-924.	1.6	62
32	Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. <i>Blood</i> , 2012, 119, 1217-1227.	1.4	61
33	Principles and problems of transfusion in sickle cell disease. <i>Seminars in Hematology</i> , 2001, 38, 315-323.	3.4	59
34	Transfusion Management in Sickle Cell Disease. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 803-826.	2.2	56
35	Role of Adhesion Molecules and Vascular Endothelium in the Pathogenesis of Sickle Cell Disease. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 84-90.	2.5	55
36	Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LU. <i>Blood</i> , 2005, 105, 3322-3329.	1.4	53

#	ARTICLE	IF	CITATIONS
37	Cellular Adhesion and the Endothelium. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 341-354.	2.2	53
38	Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease. <i>PLoS ONE</i> , 2016, 11, e0152895.	2.5	51
39	Human Erythrocyte Antigens. <i>Vox Sanguinis</i> , 1987, 52, 236-243.	1.5	50
40	Surgical and Obstetric Outcomes in Adults with Sickle Cell Disease. <i>American Journal of Medicine</i> , 2008, 121, 916-921.	1.5	48
41	Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1422-1426.	2.0	47
42	Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. <i>Haematologica</i> , 2008, 93, 481-485.	3.5	47
43	In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress. <i>PLoS Genetics</i> , 2015, 11, e1005349.	3.5	45
44	A Blood Group-related Polymorphism of CD44 Abolishes a Hyaluronan-binding Consensus Sequence without Preventing Hyaluronan Binding. <i>Journal of Biological Chemistry</i> , 1996, 271, 7147-7153.	3.4	43
45	Placenta growth factor in sickle cell disease: association with hemolysis and inflammation. <i>Blood</i> , 2010, 115, 2014-2020.	1.4	41
46	The Lutheran glycoprotein: a multifunctional adhesion receptor. <i>Transfusion</i> , 2006, 46, 668-677.	1.6	40
47	Effect of Propranolol as Antiadhesive Therapy in Sickle Cell Disease. <i>Clinical and Translational Science</i> , 2012, 5, 437-444.	3.1	40
48	Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. <i>Nature Communications</i> , 2020, 11, 6417.	12.8	39
49	Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vasoocclusion. <i>British Journal of Haematology</i> , 2016, 175, 935-948.	2.5	38
50	Characterization of the hypercoagulable state in patients with sickle cell disease. <i>Thrombosis Research</i> , 2012, 130, e241-e245.	1.7	36
51	Principles and problems of transfusion in sickle cell disease. <i>Seminars in Hematology</i> , 2001, 38, 315-323.	3.4	34
52	B-CAM/LU expression and the role of B-CAM/LU activation in binding of low- and high-density red cells to laminin in sickle cell disease. <i>American Journal of Hematology</i> , 2004, 75, 63-72.	4.1	32
53	β 2-Adrenergic receptor and adenylate cyclase gene polymorphisms affect sickle red cell adhesion. <i>British Journal of Haematology</i> , 2008, 141, 105-108.	2.5	30
54	Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed. <i>Cell Genomics</i> , 2022, 2, 100084.	6.5	29

#	ARTICLE	IF	CITATIONS
55	Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease. <i>American Journal of Hematology</i> , 2018, 93, 1451-1460.	4.1	28
56	Does Treatment with Hydroxyurea and Opioids Affect Age of Death in Sickle Cell Disease Patients?. <i>Blood</i> , 2008, 112, 4808-4808.	1.4	28
57	Human medullary thymocyte p80 antigen and In(Lu)-related p80 antigen reside on the same protein. <i>Human Immunology</i> , 1986, 17, 311-324.	2.4	26
58	Expresion of cell adhesion molecule CD44 in primary tumors of the liver: an immunohistochemical study. <i>Liver</i> , 1997, 17, 17-23.	0.1	26
59	Clonal hematopoiesis in sickle cell disease. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	26
60	Molecular interactions of B-CAM (basal-cell adhesion molecule) and laminin in epithelial skin cancer. <i>Archives of Dermatological Research</i> , 2004, 296, 59-66.	1.9	21
61	Erythrocyte webb-type glycoporphin C variant lacks N-glycosylation due to an asparagine to serine substitution. <i>American Journal of Hematology</i> , 1991, 37, 51-52.	4.1	19
62	Sickle Erythrocytes Target Cytotoxics to Hypoxic Tumor Microvessels and Potentiate a Tumoricidal Response. <i>PLoS ONE</i> , 2013, 8, e52543.	2.5	18
63	Red Cell Antigens as Functional Molecules and Obstacles to Transfusion. <i>Hematology American Society of Hematology Education Program</i> , 2002, 2002, 445-462.	2.5	17
64	Biologic functions of blood group antigens. <i>Current Opinion in Hematology</i> , 1996, 3, 473-479.	2.5	15
65	A common functional <i>PIEZO1</i> deletion allele associates with red blood cell density in sickle cell disease patients. <i>American Journal of Hematology</i> , 2018, 93, E362-E365.	4.1	15
66	Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?. <i>Blood Advances</i> , 2020, 4, 3457-3465.	5.2	14
67	Potential causal role of l-glutamine in sickle cell disease painful crises: A Mendelian randomization analysis. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 86, 102504.	1.4	14
68	Location of WESbon decay-accelerating factor. <i>Transfusion</i> , 1995, 35, 278-278.	1.6	13
69	Pulmonary Hypertension in SS, SC and \hat{S}^2 Thalassemia: Prevalence, Associated Clinical Syndromes, and Mortality.. <i>Blood</i> , 2004, 104, 1663-1663.	1.4	13
70	Effects of Single Nucleotide Polymorphisms of the $\hat{I}22$ Adrenergic Receptor and of Adenylate Cyclase on Sickle Red Cell Adhesion to Laminin.. <i>Blood</i> , 2004, 104, 3565-3565.	1.4	13
71	FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. <i>Blood</i> , 2020, 136, 19-20.	1.4	12
72	D, weak D (Du), and partial D: the molecular story unfolds. <i>Transfusion</i> , 1996, 36, 97-100.	1.6	11

#	ARTICLE	IF	CITATIONS
73	Paroxysmal cold hemoglobinuria and cardiopulmonary bypass. <i>Annals of Thoracic Surgery</i> , 2003, 75, 579-581.	1.3	11
74	RNA Aptamer Therapy for Vaso-Occlusion in Sickle Cell Disease. <i>Nucleic Acid Therapeutics</i> , 2011, 21, 275-283.	3.6	11
75	Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis. <i>Haematologica</i> , 2021, 106, 1749-1753.	3.5	11
76	Relationship of In ^b Antigen to Other Antigens on In(Lu)-related p80. <i>Vox Sanguinis</i> , 1990, 58, 118-121.	1.5	10
77	Thrombospondin β 1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemia. <i>American Journal of Hematology</i> , 2017, 92, E31-E34.	4.1	10
78	A multi-institutional comparison of younger and older adults with sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E115-E117.	4.1	9
79	Nitric oxide loading reduces sickle red cell adhesion and vaso-occlusion in vivo. <i>Blood Advances</i> , 2019, 3, 2586-2597.	5.2	9
80	Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. <i>Blood</i> , 2020, 136, 18-19.	1.4	9
81	Sevuparin Reduces Adhesion Of Both Sickle Red Cells and Leukocytes To Endothelial Cells In Vitro and Inhibits Vaso-Occlusion In Vivo. <i>Blood</i> , 2013, 122, 182-182.	1.4	9
82	AN ANTIBODY TO HUMAN THYMIC HASSALL'S BODY EPITHELIUM RECOGNIZES A SUBSET OF BLOOD GROUP A ANTIGENS. <i>International Journal of Immunogenetics</i> , 1985, 12, 3-15.	1.2	8
83	Blood group antigens on complement receptor/regulatory proteins. <i>Transfusion Medicine Reviews</i> , 1995, 9, 20-28.	2.0	8
84	Developing new pharmacotherapeutic approaches to treating sickle cell disease. <i>ISBT Science Series</i> , 2017, 12, 239-247.	1.1	8
85	Prophylactic Dose Low Molecular Weight Heparin (dalteparin) For Treatment Of Vaso-Occlusive Pain Crisis In Patients With Sickle Cell Disease. <i>Blood</i> , 2013, 122, 2241-2241.	1.4	8
86	Relationship of In ^b Antigen to Other Antigens on In(Lu)-related p80. <i>Vox Sanguinis</i> , 1990, 58, 118-121.	1.5	7
87	Diversity of variant alleles encoding Kidd, Duffy, and Kell antigens in individuals with sickle cell disease using whole genome sequencing data from the NHLBI TOPMed Program. <i>Transfusion</i> , 2021, 61, 603-616.	1.6	7
88	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. <i>Blood</i> , 2013, 122, 776-776.	1.4	7
89	Human Erythrocyte Antigens. <i>Vox Sanguinis</i> , 1987, 52, 236-243.	1.5	6
90	Monoclonal Antibody Recognizing a Unique Rh-Related Specificity. <i>Vox Sanguinis</i> , 1993, 64, 231-239.	1.5	6

#	ARTICLE	IF	CITATIONS
91	Genetic Polymorphisms Associated with Risk for Pulmonary Hypertension and Proteinuria in Sickle Cell Disease.. Blood, 2004, 104, 1668-1668.	1.4	6
92	GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease. Blood, 2010, 116, 1632-1632.	1.4	6
93	Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects. Blood, 2019, 134, 616-616.	1.4	6
94	Biomarkers and recent advances in the management and therapy of sickle cell disease. F1000Research, 2015, 4, 1050.	1.6	5
95	Epinephrine-Induced Sickle Red Cell Adhesion and Vaso-Occlusion In Vivo Is Inhibited by the Î²-Adrenoceptor Blocker Propranolol.. Blood, 2004, 104, 364-364.	1.4	5
96	Clinical and Genetic Profiles of the Aging Sickle Cell Patient.. Blood, 2005, 106, 75-75.	1.4	5
97	Effects of Hydroxyurea (HU) and Magnesium Pidolate (Mg) in Hemoglobin SC Disease (HbSC): the â€œCHAMPSâ€•Trial.. Blood, 2009, 114, 819-819.	1.4	5
98	A case report: IgG autoanti-N as a cause of severe autoimmune hemolytic anemia. Immunohematology, 1990, 6, 83-86.	0.2	5
99	Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis. Blood Advances, 2022, 6, 4461-4470.	5.2	5
100	Introduction of the term â€œpartial Dâ€• Transfusion, 1996, 36, 761-762.	1.6	4
101	The Relationship of Opioid Analgesia toÂQuality of Life in an Adult Sickle Cell Population. Health Outcomes Research in Medicine, 2010, 1, e29-e37.	0.6	4
102	An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE). Blood, 2020, 136, 19-20.	1.4	4
103	Effect of Single Dose In Vivo Propranolol Therapy on In Vitro Adhesion of Human SS RBC.. Blood, 2006, 108, 1234-1234.	1.4	4
104	Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis. Blood, 2014, 124, 2704-2704.	1.4	4
105	Factors Related to the Progression of Sickle Cell Disease Nephropathy. Blood, 2016, 128, 9-9.	1.4	4
106	Clinical Characteristics Associated with Survival in Adult Sickle Cell Disease. Blood, 2012, 120, 3229-3229.	1.4	4
107	It really IS the red cell. Blood, 2008, 112, 459-460.	1.4	3
108	RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes. PLoS ONE, 2019, 14, e0217042.	2.5	3

#	ARTICLE	IF	CITATIONS
109	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts. PLoS ONE, 2020, 15, e0237543.	2.5	3
110	Adherence with Hydroxyurea in Children with Sickle Cell Disease. Blood, 2008, 112, 167-167.	1.4	3
111	Identification of optimal thalassemia screening strategies for migrant populations in Thailand using a qualitative approach. BMC Public Health, 2021, 21, 1796.	2.9	3
112	In Vivo Modeling Of Genetic Mechanisms Associated With Sickle Cell Disease Nephropathy. Blood, 2013, 122, 2224-2224.	1.4	3
113	Lutheran Antigens, Lutheran Regulatory Genes, and Lutheran Regulatory Gene Targets. Blood Cell Biochemistry, 1995, , 281-297.	0.3	3
114	Large-scale use of red blood cell units containing alloantibodies. Immunohematology, 2000, 16, 120-123.	0.2	3
115	Feasibility of and barriers to thalassemia screening in migrant populations: a cross-sectional study of Myanmar and Cambodian migrants in Thailand. BMC Public Health, 2021, 21, 1177.	2.9	2
116	Blocking Adhesion of Sickle Erythrocytes to Endothelial P-Selectin Using an RNA Aptamer.. Blood, 2007, 110, 147-147.	1.4	2
117	Genome-Wide Studies in Sickle Cell Anemia Show Associations Between SNPs in the Olfactory Receptor Gene Cluster and Fetal Hemoglobin Concentration.. Blood, 2009, 114, 821-821.	1.4	2
118	An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 â€“ A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia. Blood, 2013, 122, 2206-2206.	1.4	2
119	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. Blood, 2013, 122, 775-775.	1.4	2
120	The Use of Genotyping in Transfusion Medicine. , 2014, 11, .		2
121	6 Minute Walk Test Outcomes in Sickle Cell Disease. Blood, 2008, 112, 4788-4788.	1.4	2
122	Knowledge, Cultural, and Structural Barriers to Thalassemia Screening in Migrant Populations in Thailand. Blood, 2018, 132, 2228-2228.	1.4	2
123	Phosphatidylinositol-linked red blood cell membrane proteins and blood group antigens. Immunohematology, 1991, 7, 37-39.	0.2	2
124	Dynamic quantitative microscopy and nanoscopy of red blood cells in sickle cell disease. Proceedings of SPIE, 2012, , .	0.8	1
125	Genome Wide Association Analysis of Iron Overload in the Trans-Omics for Precision Medicine (TOPMed) Sickle Cell Disease Cohorts. Blood, 2020, 136, 52-52.	1.4	1
126	Left Sided Heart Dysfunction in Sickle Cell Disease: Echocardiographic and Genetic Studies.. Blood, 2005, 106, 78-78.	1.4	1

#	ARTICLE	IF	CITATIONS
127	Use of a Computer Based Neurocognitive Software Program in Asymptomatic Neurologically Intact Adults with Sickle Cell Disease.. Blood, 2009, 114, 1524-1524.	1.4	1
128	Polymorphisms in TNF α Are Associated with Cerebrovascular Events in Sickle Cell Disease.. Blood, 2009, 114, 1540-1540.	1.4	1
129	Genetic Polymorphisms in NEDD4L Are Associated with Pulmonary Hypertension of Sickle Cell Anemia.. Blood, 2009, 114, 2562-2562.	1.4	1
130	Initial Experience with the IMPROVE Trial-a Phase III Analgesic Trial for Hospitalized Sickle Cell Painful Episodes. Blood, 2010, 116, 2667-2667.	1.4	1
131	Hydroxyurea Induces Genome-Wide Epigenetic Changes In Sickle Cell Disease. Blood, 2010, 116, 2670-2670.	1.4	1
132	Sickle Red Blood Cell Induced Adhesion of Neutrophils to Endothelial Cells and Biologic Correlates of Leukocyte Activation. Blood, 2011, 118, 1055-1055.	1.4	1
133	Inflammatory Polymorphisms Link the Risk of Acute Chest Syndrome with Asthma in Adults with Sickle Cell Disease. Blood, 2011, 118, 1072-1072.	1.4	1
134	Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State. Blood, 2012, 120, 87-87.	1.4	1
135	Genes Associated with Survival in Adult Sickle Cell Disease. Blood, 2014, 124, 2719-2719.	1.4	1
136	Role of LW and AKAP79 in β -Adrenergic Receptor Signaling-Induced Sickle Red Blood Cell Adhesion.. Blood, 2005, 106, 3181-3181.	1.4	1
137	Current Prevalence of Specific Clinical Outcomes in Adult Patients with Hb SS or Hb S β 0 Thalassemia.. Blood, 2006, 108, 1201-1201.	1.4	1
138	Identification of Optimal Thalassemia Screening Strategies for Migrant Populations in Thailand: A Mixed-Methods Approach. Blood, 2019, 134, 2112-2112.	1.4	1
139	Identification of the <i>Tc^b</i> allele of the Cromer blood group gene by PCR and RFLP analysis. Immunohematology, 1995, 11, 1-4.	0.2	1
140	Pyridoxamine: another vitamin for sickle cell disease?. Haematologica, 2020, 105, 2348-2350.	3.5	1
141	Protein Kinases Associated with Activation of Sickle Red Blood Cell Adhesion.. Blood, 2004, 104, 3567-3567.	1.4	0
142	Priapism in SCD: Clinical and Genetic Correlations.. Blood, 2005, 106, 3174-3174.	1.4	0
143	Blocking Adhesion of Sickle Erythrocytes to Endothelial β 3 Using RNA Aptamer.. Blood, 2006, 108, 688-688.	1.4	0
144	Innovative Drug Design Using RNA Aptamers for Various Anemias. Oncology & Hematology Review, 2007, 00, 55.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Exploring Childhood Risk Factors That Predict End-Organ Damage in Adults with Sickle Cell Disease: The ASH Workshop on Sickle Cell Disease. , 2007, 4, .		0
146	The Effects of Chronic Opiates Pain Therapy in Sickle Cell Anemia.. Blood, 2007, 110, 3404-3404.	1.4	0
147	The Relationship of Opiate Analgesia to Quality of Life in an Adult Sickle Cell Population.. Blood, 2007, 110, 2261-2261.	1.4	0
148	Hydroxyurea Therapy Increases Expression of BCAM/LU and Adhesion to Laminin in Children with Sickle Cell Disease. Blood, 2008, 112, 4806-4806.	1.4	0
149	Erythrocyte Adhesion and Phosphatidylserine Exposure in HbSC Disease: Baseline Data from the CHAMPS Study. Blood, 2008, 112, 2478-2478.	1.4	0
150	Prolonged Survival despite High Disease Burden in Elderly (≥55) Patients with Hb SS or Hb S ^β 0 Thalassemia. Blood, 2008, 112, 710-710.	1.4	0
151	Genomic Approaches to Identifying Risk for Pulmonary Artery Hypertension among Individuals with Sickle Cell Disease.. Blood, 2008, 112, 1442-1442.	1.4	0
152	Obstetric and Gynecological History in Sickle Cell Disease Females. Blood, 2008, 112, 2498-2498.	1.4	0
153	In-Hospital Outcomes Among Sickle Cell Patients with Acute Chest Syndrome: Results From a National Database.. Blood, 2009, 114, 1367-1367.	1.4	0
154	Retrospective Review of the Natural History of Pulmonary Hypertension in Sickle Cell Disease Demonstrates That Progressive Enlargement of the Left Atrium Is a Strong Predictor of Death.. Blood, 2009, 114, 1529-1529.	1.4	0
155	Comparison of Thrombin Generation of Sickle Cell Patients in Microparticle Rich and Microparticle Poor Plasma Using Thrombin Generation Assay (TGA).. Blood, 2009, 114, 2557-2557.	1.4	0
156	S-Nitrosylation of Rap1 and Relationship to Rap1 Activity and Disease Status In SCD. Blood, 2010, 116, 2662-2662.	1.4	0
157	Factors Associated with Heterocellular Aggregate Formation In Sickle Cell Disease. Blood, 2010, 116, 2669-2669.	1.4	0
158	Genetic Variation In MYH9 Is Associated with Sickle Cell Disease Nephropathy. Blood, 2010, 116, 1648-1648.	1.4	0
159	Atypical Activation of Plasma Membrane-Bound ERK1/2 Is Associated with Regulation of Sickle Red Cell Adhesion to Endothelium. Blood, 2010, 116, 266-266.	1.4	0
160	Anti-Inflammatory Markers Are Associated with Glomerular Filtration Rate In Adults with Sickle Cell Disease.. Blood, 2010, 116, 1652-1652.	1.4	0
161	Relationship of Soluble Adhesion Receptors to Red Cell Apoptosis In SCD.. Blood, 2010, 116, 1654-1654.	1.4	0
162	An Elevated Tricuspid Regurgitant Jet Velocity in Sickle Cell Disease Is Associated with Polymorphisms in Genes Impacting Innate Immunity. Blood, 2011, 118, 514-514.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Novel Optical Signature for Sickle Cell Trait Red Blood Cells. , 2012, , .		0
164	Genetic and Epigenetic Regulation of the Gamma Globin Locus Is Associated with Fetal Hemoglobin Levels and Frequency of Pain in Sickle Cell Disease. Blood, 2012, 120, 3230-3230.	1.4	0
165	Restoring Endogenous Nitric Oxide in Sickle or Transfused Red Cells Ameliorates Adhesion and Vaso-Occlusion in Vivo. Blood, 2012, 120, 3251-3251.	1.4	0
166	Paradoxical Effects Of Tumor Necrosis Factor-Alpha On Endothelial Adhesion Of Stored Human Red Blood Cells. Blood, 2013, 122, 2399-2399.	1.4	0
167	Expression of Human Erythrocyte Membrane Protein Antigens during Erythroid Differentiation. Blood Cell Biochemistry, 1990, , 27-43.	0.3	0
168	Effects of Sulforaphane Obtained from Broccoli Sprout Homogenate in Patients with Sickle Cell Disease (SCD). Blood, 2014, 124, 4931-4931.	1.4	0
169	Genome-Wide Evaluation of Epistasis with APOL1 Risk Variants in Sickle Cell Disease Nephropathy. Blood, 2015, 126, 3401-3401.	1.4	0
170	Use of Mobile Technology to Monitor Pain and Reduce Outpatient, Emergency Department (ED), and Hospital Visits for Sickle Cell Pain Crisis. Blood, 2016, 128, 2390-2390.	1.4	0
171	CWAS Meta-Analysis of Glomerular Filtration Rate in Three Cohorts of Sickle Cell Disease Patients and In Vivo Functional Analysis Reveals Potential Nephropathy Candidate Genes. Blood, 2016, 128, 269-269.	1.4	0
172	Thrombospondin-1 Polymorphisms Are Associated with Chronic Kidney Disease in Sickle Cell Anemia. Blood, 2016, 128, 2491-2491.	1.4	0
173	Effect of FXIII Polymorphism on Formation of Heterocellular Aggregates in SCD. Blood, 2016, 128, 3648-3648.	1.4	0
174	Mechanism Underlying a Role for Factor XIII (FXIII) Polymorphism in Sickle Cell Disease-Associated Priapism. Blood, 2018, 132, 2361-2361.	1.4	0
175	Title is missing!. , 2020, 15, e0237543.		0
176	Title is missing!. , 2020, 15, e0237543.		0
177	Title is missing!. , 2020, 15, e0237543.		0
178	Title is missing!. , 2020, 15, e0237543.		0
179	Title is missing!. , 2020, 15, e0237543.		0
180	Title is missing!. , 2020, 15, e0237543.		0

#	ARTICLE	IF	CITATIONS
181	Functions of Blood Group Antigens. , 0, , 241-250.		0